Altair
Skip to content

Trading Analysis Report: MELI

Analysis date: 2026-10-03 · Model: gpt-6-sol · AI-generated, not financial advice.

  • Analysis date: 2026-10-03
  • Rating: Underweight
  • Generated: 2026-10-04 14:25:22
  • TradingAgents 0.6.0: openai, deep gpt-6-sol, quick gpt-6-sol
  • Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
  • Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

V. Portfolio Manager Decision

Rating: Underweight

Executive Summary: Underweight MELI over 1–3 months: obtain a fresh quote, then trim an oversized holding in stages toward no more than roughly half a standard allocation, or less if concentration and portfolio-wide gap-loss limits require it. Do not mechanically sell a small holding already within those limits; if uninvested, do not initiate or short. Recalculate any protective level using current volatility rather than treating the historical $1,623.75 stop as an executable or guaranteed exit.

Current Price: 1696.56

Price Target: 1679.02

Confidence: Medium

Time Horizon: 1–3 months

IV. Risk Management Team Decision

Aggressive Analyst

Aggressive Analyst: I’d make the SELL call, but I’d make it a staged trim, not a verdict that MELI’s growth story is over. The aggressive opportunity here is to stop giving a full allocation to a weakening setup while preserving a meaningful stake if the rebound comes.

MELI’s H1 gross profit grew 36.8%, yet operating income fell 18.5%. Its October 2 close of $1,696.56 was about 15.5% below the September 2 close, beneath both the $1,837.61 200-day average and the $1,860.01 daily SuperTrend line. Weekly and daily SuperTrend remain DOWN, and OBV has declined with price. Those signals make a full-sized hold a substantial bet that growth will translate back into profit before the market demands proof. Missing credit-quality evidence adds uncertainty; it does not establish that losses are worsening.

A purely defensive investor might sell every share. That misses the upside: MELI’s monthly SuperTrend is still UP, H1 operating cash flow rose, and the daily TD-9 calls for watching a rebound. A neutral “wait for Q3 and do nothing” stance has the opposite flaw: it leaves excess exposure in place while earnings and price trends disagree. The bolder middle course is to trim any existing excess toward no more than half a standard allocation, freeing risk capacity without forfeiting participation. If MELI is not held, stay at 0%; this is not a short call.

I would not mistake a bounce for confirmation. A move above the October 2 high of $1,709.36 with improving participation is a first test, not a reversal; the moving average and daily SuperTrend are tougher hurdles. Obtain a fresh price and Q3 results before changing the underweight stance. The proposed $1,623.75 stop is only an illustrative level for a remaining long: verify current volatility, size it to a fixed dollar-risk budget, and allow for gap risk. Aggressive Analyst: Conservative Analyst, the 15.5% decline, falling OBV, and daily and weekly SuperTrend DOWN readings make the case for selling MELI excess, not for treating 25% of a standard allocation as the natural ceiling. H1 operating income fell 18.5%, but gross profit rose 36.8%, and operating cash flow less capex rose from $3.389 billion to $5.025 billion. That cash-flow measure is not necessarily available to shareholders, and missing credit-quality data is a serious gap. Neither, though, establishes that MELI’s growth engine or lending performance has broken. Your quarter-size ceiling risks surrendering participation just as the daily TD-9 flags rebound risk and the monthly SuperTrend remains UP.

Neutral Analyst, I agree that half an allocation is not automatically safe; it is an upside-preserving ceiling, not a default holding or a floor. But your one-third working reference can quietly turn a risk-budget decision into another mechanical trim. You acknowledge that a diversified, well-funded portfolio might retain closer to half. I would make that the practical upper bound when the caller’s concentration and fixed dollar-risk limits permit it. From the last verified $1,696.56 close, the $1,837.61 200-day average was about 8.3% higher. That is a hurdle, not a price target, but reducing from half to one-third gives up a third of the shares that could participate in a recovery. Waiting for Q3 before adding makes sense; waiting for it before preserving any meaningful stake may mean buying back after the first move.

Neither analyst should mistake that upside argument for a claim that MELI has reversed. RSI was only 33.49, the MACD histogram remained negative, credit losses need checking, and the revenue data do not support a confident valuation case. The 9-to-5 bullish split among tagged StockTwits posts is too thin and concentrated to settle the issue. Higher U.S. yields are a real headwind, while the supplied FX readings are too stale to establish a current currency move. These uncertainties argue against a full allocation—not automatically for a near-exit.

My MELI call remains SELL as a staged trim: after obtaining a fresh quote, reduce any existing excess toward no more than about half a standard allocation, or less if the caller’s risk budget requires it. Do not mechanically sell a smaller, risk-controlled holding; if MELI is not held, stay at 0% and do not short. Reassess after fresh prices and Q3 results, including credit quality. The historical $1,623.75 stop needs recalculation against current volatility, and no stop eliminates gap risk. Aggressive Analyst: Conservative Analyst, MELI’s profit decline and missing credit-quality figures justify selling excess exposure. They do not establish that a quarter of a standard allocation is the right ceiling. H1 gross profit grew 36.8%, and operating cash flow less capex rose from $3.389 billion to $5.025 billion. I would not call that cash freely available to shareholders, or infer that lending losses are contained. But cutting a risk-controlled holding to a quarter gives up substantial participation if earnings recover before the next disclosure. The monthly SuperTrend is still UP, and the daily TD-9 flags rebound risk. Neither is a buy signal; together, they make a near-exit an aggressive bet of its own.

Neutral Analyst, I agree that the 200-day average, about 8.3% above MELI’s last verified $1,696.56 close, is a hurdle—not a forecast—and that a half allocation carries more downside than a quarter if MELI gaps lower. That is why half should be an upside-preserving maximum when the caller’s risk limits allow it, never a default position. Your 25%–50% range leaves the consequential choice unresolved. My choice is to preserve the option of meaningful participation while selling enough to respect concentration and fixed dollar-risk limits. Waiting for both Q3 credit evidence and a durable trend reversal before retaining meaningful exposure risks missing the first stage of a recovery.

The SELL case remains strong: MELI closed below its $1,837.61 200-day average and $1,860.01 daily SuperTrend, daily and weekly SuperTrend are DOWN, and OBV has fallen. High U.S. yields add a headwind; the available FX observations are too stale to claim a current move. I would not use thin, low-confidence social sentiment to override those signals. But neither the downtrend nor the uncertain credit picture proves that MELI’s commerce-and-fintech growth has failed.

So I would obtain a fresh quote, then SELL existing MELI excess in stages toward no more than about half a standard allocation, and less if concentration or fixed dollar-risk limits require it. Do not mechanically sell a smaller holding already within those limits. If MELI is not held, remain at 0% and do not short. The historical $1,623.75 stop must be recalculated using current price and volatility; size the remainder for the entry-to-stop risk and a possible gap beyond it. Reassess the underweight stance only with fresh prices and Q3 profit and credit-quality results—not on a TD-9 count or a single bounce. Aggressive Analyst: Conservative Analyst, MELI’s missing credit-quality figures are a reason to sell excess exposure, not evidence that a quarter-allocation ceiling is better than a risk-tested half. I agree that H1 operating income fell 18.5% despite 36.8% gross-profit growth, and I would not treat the $5.025 billion cash-flow-less-capex figure as cash freely available to shareholders. But those figures also show why cutting a tolerable position to a near-exit has a cost: MELI’s growth engine is still expanding, and a profit recovery could begin before the next disclosure. The monthly SuperTrend UP and daily TD-9 do not answer the credit question; they flag the participation a quarter-sized stake would surrender if a rebound starts.

You are right to demand a loss test beyond the stop, including correlated holdings. I would apply it to MELI rather than assume that 25% is the answer before knowing the portfolio or a current quote. Half a standard allocation is a maximum if concentration, fixed dollar-risk and gap-stress budgets all permit it—not a minimum. If those tests support only a quarter, sell to a quarter. The historical $1,623.75 stop is neither an executable current level nor protection against a gap.

Neutral Analyst, your stress tests improve the decision, but a one-third “review point” is no more evidence-based than the conservative analyst’s quarter. MELI’s October 2 close of $1,696.56 sat about 8.3% below its 200-day average and 9.6% below its daily SuperTrend line. Those are recovery hurdles, not forecasts. Still, retaining half rather than one-third gives a risk-capable portfolio 50% more shares participating if MELI reaches those tests. Waiting for Q3 before adding makes sense; requiring Q3 and a durable reversal before preserving a meaningful existing stake risks missing the first move.

My MELI call remains SELL: obtain a fresh quote and volatility reading, then trim existing excess in stages toward no more than half a standard allocation, or further if concentration and stress-loss limits require it. Do not mechanically sell a smaller holding that passes those tests. If MELI is not held, remain at 0% and do not short. Keep the underweight stance until fresh prices and reported Q3 profit and credit-quality results justify changing it—not merely a one-day bounce. Aggressive Analyst: Conservative Analyst, you are right that keeping half a standard allocation in MELI means more exposure to a credit or earnings gap than keeping a quarter. But that arithmetic does not make a quarter the better ceiling. H1 operating income fell 18.5% despite 36.8% gross-profit growth, and missing delinquency and provision figures demand restraint. They do not establish that credit losses are worsening. Meanwhile, H1 operating cash flow less capex rose from $3.389 billion to $5.025 billion. I would not call that cash freely available to shareholders, but dismissing the growth and cash-generation evidence risks cutting MELI to a token stake before profit recovers.

Your gap concern is stronger than any stop-based calculation: a modeled loss can be too small, and correlated rate-sensitive holdings can compound it. I would stress-test the whole portfolio and reduce MELI below half if that test requires it. What I challenge is making 25% the provisional answer before seeing the caller’s holdings, loss tolerance or a fresh quote. The monthly SuperTrend remains UP and the daily TD-9 flags rebound risk. Neither reverses the daily and weekly downtrends, but both make an early recovery worth retaining the capacity to participate in.

Neutral Analyst, I agree that a risk test permitting half does not require half. Still, refusing to favor any size after the tests pass leaves the upside decision unresolved. For a portfolio that can absorb a stressed gap, I would favor retaining up to half rather than trimming by reflex toward one-third: half holds 50% more MELI shares than one-third if a recovery develops. It also carries 50% more share-level downside—that is precisely why concentration and gap-loss budgets must be binding, not ceremonial. Requiring both Q3 evidence and a durable trend recovery before preserving an existing stake could mean selling the first leg of that opportunity.

This is still a SELL, not a reversal call. MELI’s last verified $1,696.56 close was below its $1,837.61 200-day average and $1,860.01 daily SuperTrend, with falling OBV. Those are reasons to remove excess exposure now, not to add on a bounce above $1,709.36. Obtain a fresh quote and volatility reading, then trim an existing MELI holding in stages toward no more than about half a standard allocation—or less if concentration, fixed-loss or portfolio gap-stress limits demand it. Do not mechanically sell a smaller holding that passes those limits. If MELI is not held, remain at 0% and do not short. The $1,623.75 stop is historical and cannot cap a gap; keep the underweight stance until fresh prices and reported Q3 profit and credit-quality figures support a change.